119 related articles for article (PubMed ID: 38640747)
1. Comment on BRAFV600E mutation does not predict lymph node metastases and recurrence in Chinese papillary thyroid microcarcinoma patients.
Sekar D
Oral Oncol; 2024 May; 152():106812. PubMed ID: 38640747
[No Abstract] [Full Text] [Related]
2. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
3. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.
Alzahrani AS; Xing M
Endocr Relat Cancer; 2013 Feb; 20(1):13-22. PubMed ID: 23132792
[TBL] [Abstract][Full Text] [Related]
4. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
Park VY; Kim EK; Lee HS; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555
[TBL] [Abstract][Full Text] [Related]
5. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.
Li F; Chen G; Sheng C; Gusdon AM; Huang Y; Lv Z; Xu H; Xing M; Qu S
Endocr Relat Cancer; 2015 Apr; 22(2):159-68. PubMed ID: 25593071
[TBL] [Abstract][Full Text] [Related]
6. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
[TBL] [Abstract][Full Text] [Related]
7. Predictors for central lymph node metastases in CN0 papillary thyroid microcarcinoma (mPTC): A retrospective analysis of 1304 cases.
Zhang Q; Wang Z; Meng X; Duh QY; Chen G
Asian J Surg; 2019 Apr; 42(4):571-576. PubMed ID: 30348606
[TBL] [Abstract][Full Text] [Related]
8. BRAF
Zhao H; Liu CH; Lu Y; Liu SZ; Yeerkenbieke P; Cao Y; Xia Y; Gao LY; Liu YW; Liu ZW; Chen SG; Liang ZY; Li XY
Oral Oncol; 2024 May; 152():106755. PubMed ID: 38547780
[TBL] [Abstract][Full Text] [Related]
9. Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis.
Jeon MJ; Chun SM; Lee JY; Choi KW; Kim D; Kim TY; Jang SJ; Kim WB; Shong YK; Song DE; Kim WG
Endocrine; 2019 Apr; 64(1):130-138. PubMed ID: 30645724
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation.
Virk RK; Van Dyke AL; Finkelstein A; Prasad A; Gibson J; Hui P; Theoharis CG; Carling T; Roman SA; Sosa JA; Udelsman R; Prasad ML
Mod Pathol; 2013 Jan; 26(1):62-70. PubMed ID: 22918165
[TBL] [Abstract][Full Text] [Related]
11. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis.
Oler G; Ebina KN; Michaluart P; Kimura ET; Cerutti J
Clin Endocrinol (Oxf); 2005 Apr; 62(4):509-11. PubMed ID: 15807885
[No Abstract] [Full Text] [Related]
12. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry.
McKelvie PA; Chan F; Yu Y; Waring P; Gresshoff I; Farrell S; Williams RA
Pathology; 2013 Dec; 45(7):637-44. PubMed ID: 24247620
[TBL] [Abstract][Full Text] [Related]
13. The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.
Park VY; Kim EK; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2016 Jul; 95(29):e4292. PubMed ID: 27442672
[TBL] [Abstract][Full Text] [Related]
14. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
15. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
Bernstein J; Virk RK; Hui P; Prasad A; Westra WH; Tallini G; Adeniran AJ; Udelsman R; Sasaki CT; Roman SA; Sosa JA; Prasad ML
Thyroid; 2013 Dec; 23(12):1525-31. PubMed ID: 23682579
[TBL] [Abstract][Full Text] [Related]
16. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
17. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
[TBL] [Abstract][Full Text] [Related]
18. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.
Zheng X; Wei S; Han Y; Li Y; Yu Y; Yun X; Ren X; Gao M
Ann Surg Oncol; 2013 Jul; 20(7):2266-73. PubMed ID: 23370668
[TBL] [Abstract][Full Text] [Related]
19. Synchronous and Metastatic Papillary and Follicular Thyroid Carcinomas with Unique Molecular Signatures.
Cracolici V; Mujacic I; Kadri S; Alikhan M; Niu N; Segal JP; Rosen LE; Sarne DH; Morgan A; Desouky S; Cipriani NA
Endocr Pathol; 2018 Mar; 29(1):9-14. PubMed ID: 28710706
[TBL] [Abstract][Full Text] [Related]
20. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
Choi SY; Park H; Kang MK; Lee DK; Lee KD; Lee HS; Kim SW; Lee EN; Hong JC
World J Surg Oncol; 2013 Nov; 11():291. PubMed ID: 24228637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
